secwatch.observer — SEC 8-K summary
======================================

Issuer:     Arcturus Therapeutics Holdings Inc. (ARCT)
CIK:        0001768224
Form:       8-K
Filed at:   2024-08-05T23:59:59+00:00
Accession:  0001193805-24-000990
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Arcturus Q2 revenue $49.9M, net loss $17.2M; pipeline advances, Kostaive launch on track
--------------------------------------------------------------------------------

- Revenue $49.9M, up $39.4M YoY from $10.5M, driven by CSL collaboration revenue.
- Net loss $17.2M ($0.64 per share) improved from $52.6M loss in Q2 2023.
- Cash $317.2M; cash runway extends through Q1 2027; $437.1M received from CSL to date.
- IND submitted for ARCT-032 Phase 2 cystic fibrosis study; ARCT-810 OTC deficiency interim data expected Q4 2024.
- Kostaive on track for Q4 commercial launch in Japan; EMA review ongoing; COVID/flu programs with CSL progressing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1768224/000119380524000990/0001193805-24-000990-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1768224/000119380524000990/e663815_8k-arct.htm
  HTML page:      https://secwatch.observer/filing/0001193805-24-000990

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer